Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

被引：4

作者：

Kwak, Hye Won ^{[1
,2
,3
]}

Park, Hyo-Jung ^{[1
,2
]}

Jung, Seo-Yeon ^{[4
]}

Oh, Eun Young ^{[5
]}

Park, Sang-In ^{[6
]}

Kim, Yeonhwa ^{[5
]}

Park, Hyeong-Jun ^{[1
,2
,3
]}

Park, Sohyun ^{[5
]}

Kim, You-Jin ^{[7
]}

Ko, Hae Li ^{[6
]}

Lee, Jung-Ah ^{[7
]}

Won, Hyeran ^{[7
]}

Hwang, Yun-Ho ^{[7
]}

Kim, Seo Yeon ^{[7
]}

Kim, Se Eun ^{[7
]}

Bae, Seoung Eun ^{[8
]}

Yoon, Minhyuk ^{[8
]}

Kim, Jae-Ouk ^{[8
]}

Song, Manki ^{[8
]}

Lee, Su Jeen ^{[4
]}

Seo, Ki-Weon ^{[4
]}

Lee, Kunse ^{[4
]}

Kim, Dokeun ^{[7
]}

Kim, Hun ^{[4
]}

Lee, Sang-Myeong ^{[5
]}

Hong, So-Hee ^{[9
]}

Nam, Jae-Hwan ^{[1
,2
,10
]}

机构：

[1] Catholic Univ Korea, Dept Med & Biol Sci, Gyeonggi Do, Bucheon, South Korea

[2] Catholic Univ Korea, BK Plus Dept Biotechnol, Gyeonggi Do, Bucheon, South Korea

[3] SML Biopharm, Gyeonggi Do, Bucheon, South Korea

[4] SK Biosci, Dept R&D, Pangyoro, South Korea

[5] Chungbuk Natl Univ, Coll Vet Med, Cheongju 28644, South Korea

[6] Scripps Korea Antibody Inst, Div Res Program, Chunchon, Kangwon Do, South Korea

[7] Natl Inst Hlth, Natl Inst Infect Dis, Ctr Vaccine Res, Div Infect Dis Vaccine Res, Sejong, South Korea

[8] Int Vaccine Inst, Sci Unit, Seoul 08826, South Korea

[9] Ewha Womans Univ, Coll Med, Dept Microbiol, Seoul 07804, South Korea

[10] Catholic Univ Korea, Dept Med & Biol Sci, 43-1 Yeokgok Dong, Bucheon 14662, South Korea

来源：

VACCINE | 2023年 / 41卷 / 11期

基金：

新加坡国家研究基金会;

关键词：

SARS-CoV-2; Measles virus vector; Neutralizing antibody; VACCINE;

D O I：

10.1016/j.vaccine.2023.02.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vari-ants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vac-cine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vacci-nation. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the a, b, c, and d variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.(c) 2023 Elsevier Ltd. All rights reserved.

引用

页码：1892 / 1901

页数：10

共 50 条

[31] Calreticulin Regulates SARS-CoV-2 Spike Protein Turnover and Modulates SARS-CoV-2 Infectivity
Rahimi, Nader
White, Mitchell R.
Amraei, Razie
Lotfollahzadeh, Saran
Xia, Chaoshuang
Michalak, Marek
Costello, Catherine E.
Muhlberger, Elke
CELLS, 2023, 12 (23)
[32] Duration of SARS-CoV-2 Serum-Neutralizing Antibodies Against SARS-CoV-2 Dependent on the Individual
Li, Jin
Zou, Li
Li, Shaojie
Zou, Ruogu
Fang, Zhixiong
Zhang, Pingan
Li, Huijun
Wang, Shanshan
Ke, Dong
Gao, Peng
Jin, Cuicui
Fang, Cong
Zhou, Ji
He, Ellen
Skog, Sven
VIRAL IMMUNOLOGY, 2023, 36 (03) : 153 - 162
[33] Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
Tandon, Ritesh
Mitra, Dipanwita
Sharma, Poonam
McCandless, Martin G.
Stray, Stephen J.
Bates, John T.
Marshall, Gailen D.
SCIENTIFIC REPORTS, 2020, 10 (01)
[34] Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
Ritesh Tandon
Dipanwita Mitra
Poonam Sharma
Martin G. McCandless
Stephen J. Stray
John T. Bates
Gailen D. Marshall
Scientific Reports, 10
[35] Neutralizing and enhancing antibodies against SARS-CoV-2
Liu, Yafei
Arase, Hisashi
INFLAMMATION AND REGENERATION, 2022, 42 (01)
[36] Neutralizing and enhancing antibodies against SARS-CoV-2
Yafei Liu
Hisashi Arase
Inflammation and Regeneration, 42
[37] VARIANTS OF SARS-COV-2
Krzywinski, Martin
AMERICAN SCIENTIST, 2022, 110 (02) : 76 - 76
[38] On the SARS-CoV-2 Variants
Scarpa, Fabio
Branda, Francesco
Petrosillo, Nicola
Ciccozzi, Massimo
INFECTIOUS DISEASE REPORTS, 2024, 16 (02) : 289 - 297
[39] Variants of SARS-CoV-2
Lauring, Adam S.
Malani, Preeti N.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (09): : 880 - 880
[40] Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies
Troyer, Zach
Alhusaini, Najwa
Tabler, Caroline O.
Sweet, Thomas
de Carvalho, Karina Inacio Ladislau
Schlatzer, Daniela M.
Carias, Lenore
King, Christopher L.
Matreyek, Kenneth
Tilton, John C.
JOURNAL OF EXTRACELLULAR VESICLES, 2021, 10 (08)

← 1 2 3 4 5 →